

Non-clinical Development of gene therapy drug candidates based on oncospreading retroviral vectors

[a:rtiCure]
[a:rti]Cure

ONCOLOGY	Preclinical
Product Type	Split, pseudotyped-Replicating Retroviral Vectors encoding two suicide genes
Indication	1 st indication: Glioblastoma 2 nd indication: Incurable neoplasms (TNB etc.)
Target	Proliferating tumor cells
MoA(Mechanism of Action)	Expression of suicide genes (TK & CD) during replication in tumor cells and spread on tumor tissue > Treatment of prodrugs (GCV & 5-FC) > Induction of cancer cell-death and anti-tumor immunity
Competitiveness	<ul style="list-style-type: none"> - Unlike oncolytic viruses. little immune reaction against the viral vectors - No early clearance of the viral vectors after injection - Minimized recombination during reverse transcription for viral replication - Can be armed with multiple therapeutic genes, such as suicide/cytokine/CAR-targeting genes without size limitation
Development Stage	GLP-toxicity and GMP manufacturing
Route of Administration	Intra-tumoral or into tumor bed (systemic injection: under developing)